Ventracor chalks up first revenues

By Ruth Beran
Tuesday, 20 September, 2005

Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.

The company previously indicated it would reach the milestone before the end of 2005.

Saliva-based biosensor could improve heart failure detection

Scientists have created a biosensor that can rapidly detect the heart failure biomarker S100A7 in...

Melanoma-causing mutation can lie dormant in healthy skin

Researchers found many examples of the mutation in normal skin, including skin next to a mole and...

Antibiotic for drug-resistant bacteria found in plain sight

The antibiotic in question is an intermediate chemical in the natural process that produces the...

Content from other channels on our network

Cutting-edge digital health tools putting plastic, silicon and steel to the sword

Electronic prescriptions and how they are used

Webinar: Turning data protection into a business advantage

Breastfeeding challenges healthcare professionals should be prepared to address

Dr Vinod Seetharaman appointed Dedalus ANZ Chief Medical Officer

Three strategies that will enable IIoT deployment

Claroty releases AI-powered device library technology

Walkinshaw Group opens new manufacturing facility and headquarters

Li-S Energy gets ARENA funding for Australian battery cell manufacturing

Webinar: Turning data protection into a business advantage

How mandatory climate reporting is raising the bar for corporate leadership

Partnership doubles medicinal blister pack recycling

Epson Australia releases new Sustainability Impact Report

Specsavers partnership tackles optical waste